Managing Prolactinomas during Pregnancy.

Area of Science:

• Endocrinology
• Reproductive Medicine
• Oncology

Background:

• Prolactinomas, benign pituitary tumors, are the most common functional pituitary adenomas.
• They frequently cause infertility and gonadal dysfunction in patients.
• Dopamine agonists (DAs) are the primary treatment, normalizing prolactin and restoring fertility.

Purpose of the Study:

• To review the therapeutic management of prolactinomas during pregnancy.
• To emphasize the safety profile of dopamine agonist therapy in pregnant patients.

Main Methods:

• Literature review of studies on prolactinoma management during pregnancy.
• Analysis of safety data for dopamine agonists (bromocriptine and cabergoline) in pregnancy.
• Evaluation of tumor enlargement risks in pregnant patients with prolactinomas.

Main Results:

• Cabergoline is generally preferred over bromocriptine due to higher efficacy and tolerability.
• Pituitary hyperplasia during pregnancy can increase prolactinoma volume, posing risks.
• Bromocriptine has more extensive safety data in pregnancy than cabergoline, with no increased risk of pregnancy loss or premature delivery.

Conclusions:

• Dopamine agonist use should generally be discontinued upon pregnancy confirmation, except in specific cases.
• Both bromocriptine and cabergoline appear safe during pregnancy, but bromocriptine has more reported fetal exposure data.
• Careful monitoring and individualized treatment decisions are crucial for managing prolactinomas in pregnant patients.